Evidence map›Paper›PMID 35273921›Full record

ReviewFrontiers in cellular and infection microbiology2022

The Gut Microbiota in Inflammatory Bowel Disease.

Peng Qiu, Takatsugu Ishimoto, Lingfeng Fu, Jun Zhang, Zhenyong Zhang, Yang Liu

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07276464 (Characterization of the Gut Microbiota Metagenomic Signature According to Physical Fitness and Its Implications for Intestinal Health.), which is not on this map. Cited by 361 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
361citing papers in PubMed, 5 pooled it
40.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07276464 completednot on this mapstarted 2025, after this paper: background citation

Characterization of the Gut Microbiota Metagenomic Signature According to Physical Fitness and Its Implications for Intestinal Health.

TypeobservationalSponsorUniversity of Rennes 2Ran2025 to 2026Enrolled30ConditionsHealthyArmsMaximal incremental exercise test, Submaximal exercise test, Fecal sampling
3 · Its place in the literature

Who cites it

361 citing papers in PubMed, 5 syntheses or guidelines pooled it, 519 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. AdjuvantMicrobiology spectrum · 2026
    Trial
  7. Trial
  8. Trial
  9. Synthetic and systems biotechnology · 2027
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Gut Microbiota Dysbiosis MediatesImmunity, inflammation and disease · 2026
    Article
  18. Article
  19. Article
  20. Review

301 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Peng QiuDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China.
Takatsugu IshimotoDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Lingfeng FuDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Jun ZhangDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Zhenyong ZhangDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Yang LiuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
China Medical University · CNKumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiological surveys indicate that the incidence of inflammatory bowel disease (IBD) is increasing rapidly with the continuous growth of the economy. A large number of studies have investigated the relationship between the genetic factors related to the susceptibility to IBD and the gut microbiota of patients by using high-throughput sequencing. IBD is considered the outcome of the interaction between host and microorganisms, including intestinal microbial factors, abnormal immune response, and a damaged intestinal mucosal barrier. The imbalance of microbial homeostasis leads to the colonization and invasion of opportunistic pathogens in the gut, which increases the risk of the host immune response and promotes the development of IBD. It is critical to identify the specific pathogens related to the pathogenesis of IBD. An in-depth understanding of various pathogenic factors is of great significance for the early detection of IBD. This review highlights the role of gut microbiota in the pathogenesis of IBD and provides a theoretical basis for the personalized approaches that modulate the gut microbiota to treat IBD.

Indexed as

ColitisGastrointestinal MicrobiomeInflammatory Bowel DiseasesHumansIntestinal Mucosagut microbiotaIBDinflammatory bowel diseasemetabolitetreatment

Identifiers

PMID35273921
PMCPMC8902753
OpenAlexW4213294193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.